BMJ Best Practice Aspergillosis - Antifungal Treatment
December 2022
BMJ Best Practice has Isavuconazole as 1 of 2 antifungal agents of choice for Aspergillosis. Isavuconazole is well tolerated compared with Voriconazole which is the other agent of choice. Isavuconazole can be switched from intravenous to oral administration without losing bioavailability and renal impairment is not aggravated.
New Perspectives on Antimicrobial Agents: Isavuconazole
Antimicrobial Chemotherapy Perspective August 2022 DOI: https://doi.org/10.1128/aac.00177-22
'Significant advantages of isavuconazole, primarily over voriconazole but in some circumstances posaconazole as well, make it an appealing option for the management of complex patients with invasive fungal infections. These potential advantages include lack of QTc interval prolongation, more predictable pharmacokinetics, a less complicated drug interaction profile, and improved tolerability, particularly when compared to voriconazole.'
Antimicrobial Chemotherapy Perspective August 2022 DOI: https://doi.org/10.1128/aac.00177-22
'Significant advantages of isavuconazole, primarily over voriconazole but in some circumstances posaconazole as well, make it an appealing option for the management of complex patients with invasive fungal infections. These potential advantages include lack of QTc interval prolongation, more predictable pharmacokinetics, a less complicated drug interaction profile, and improved tolerability, particularly when compared to voriconazole.'
EUCAST. Isavuconazole vs. Aspergillus v 2.0 (2020)
EUCAST Rationale for Isavuconazole states routine susceptibility testing is of utmost importance because acquired resistance to triazoles has been reported among A. fumigatus isolates. Results also support the use of Isavuconazole for the primary treatment of patients with invasive mould disease.
Isavuconazole is a triazole antifungal agent with broad-spectrum in vitro activity against Aspergillus spp. and other medically important fungal pathogens. It is available for iv and oral administration as a water soluble prodrug (isavuconazonium sulphate).
It is approved for the following indications in adults • invasive aspergillosis • mucormycosis in patients for whom amphotericin B is inappropriate.
EUCAST Rationale for Isavuconazole states routine susceptibility testing is of utmost importance because acquired resistance to triazoles has been reported among A. fumigatus isolates. Results also support the use of Isavuconazole for the primary treatment of patients with invasive mould disease.
Isavuconazole is a triazole antifungal agent with broad-spectrum in vitro activity against Aspergillus spp. and other medically important fungal pathogens. It is available for iv and oral administration as a water soluble prodrug (isavuconazonium sulphate).
It is approved for the following indications in adults • invasive aspergillosis • mucormycosis in patients for whom amphotericin B is inappropriate.
|
|